{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sir Karakus G"],"funding":["Acibadem Healthcare Group","TUBITAK-BIDEB 2244-University-Industry PhD program","TÜBİTAK 2247-C Trainee Researcher Scholarship Program"],"pagination":["5804"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7970959"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["COVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, SARS-CoV-2 vaccines have become crucial for reducing morbidity and mortality. In this study, in vitro and in vivo safety and efficacy analyzes of lyophilized vaccine candidates inactivated by gamma-irradiation were performed. The candidate vaccines in this study were OZG-3861 version 1 (V1), an inactivated SARS-CoV-2 virus vaccine, and SK-01 version 1 (V1), a GM-CSF adjuvant added vaccine. The candidate vaccines were applied intradermally to BALB/c mice to assess toxicity and immunogenicity. Preliminary results in vaccinated mice are reported in this study. Especially, the vaccine models containing GM-CSF caused significant antibody production with neutra"],"journal":["Scientific reports"],"pubmed_title":["Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates."],"pmcid":["PMC7970959"],"funding_grant_id":["118C082"],"pubmed_authors":["Telci D","Akyoney S","Ozbek U","Elek M","Ratip S","Hemsinlioglu C","Tastan C","Tumentemur G","Sahin F","Turan RD","Yalcin K","Abanuz S","Ozer S","Arbak S","Sahin I","Ertop G","Sir Karakus G","Acikel Elmas M","Cakirsoy D","Dilek Kancagi D","Ovali E","Demir S","Kocagoz AS","Elibol O","Yurtsever B","Hatirnaz Ng O","Seyis U"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates.","description":"COVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, SARS-CoV-2 vaccines have become crucial for reducing morbidity and mortality. In this study, in vitro and in vivo safety and efficacy analyzes of lyophilized vaccine candidates inactivated by gamma-irradiation were performed. The candidate vaccines in this study were OZG-3861 version 1 (V1), an inactivated SARS-CoV-2 virus vaccine, and SK-01 version 1 (V1), a GM-CSF adjuvant added vaccine. The candidate vaccines were applied intradermally to BALB/c mice to assess toxicity and immunogenicity. Preliminary results in vaccinated mice are reported in this study. Especially, the vaccine models containing GM-CSF caused significant antibody production with neutra","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-07-16T10:10:18.61Z","creation":"2025-04-21T17:10:41.255Z"},"accession":"S-EPMC7970959","cross_references":{"pubmed":["33707532"],"doi":["10.1038/s41598-021-83930-6"]}}